Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Protagonist Therapeutics, Inc. - Common Stock
(NQ:
PTGX
)
133.25
+0.97 (+0.73%)
Streaming Delayed Price
Updated: 10:49 AM EDT, Aug 4, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Protagonist Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
Protagonist Therapeutics (NASDAQ:PTGX): A High Growth Momentum Stock Meeting the Mark Minervini Technical Setup
↗
July 22, 2026
Via
Chartmill
Protagonist Therapeutics (NASDAQ:PTGX) Shows Technical Strength and High Growth Momentum
↗
June 13, 2026
Via
Chartmill
Why This Fund Made a $189 Million Bet on Erasca as Shares Skyrocket 800%
↗
May 29, 2026
This clinical-stage biotech develops targeted oral therapies for RAS/MAPK-driven cancers, with all assets currently in development.
Via
The Motley Fool
Topics
Regulatory Compliance
Tango Therapeutics Stock Is Up 840%, and This Fund Just Disclosed Buying $164 Million More
↗
May 29, 2026
This biotechnology firm advances targeted cancer therapies, leveraging genetic insights and strategic partnerships in oncology.
Via
The Motley Fool
BMO Capital Lifts Protagonist Therapeutics Target On J&J Deal Hopes — Retail Traders Pile In
↗
October 14, 2025
Via
Stocktwits
Hedge Fund Wagers $36 Million on Biotech Denali After First FDA Approval
↗
May 18, 2026
This biotech develops therapies for neurodegenerative diseases, advancing a broad pipeline through strategic pharmaceutical partnerships.
Via
The Motley Fool
Topics
Regulatory Compliance
Hedge Fund Drops $40 Million on Gene-Editing Biotech Beam. Is It a Buy?
↗
May 18, 2026
Beam Therapeutics develops precision genetic medicines using base editing technology to target serious inherited diseases.
Via
The Motley Fool
Hedge Fund Drops $37 Million on Rare Disease Biotech Crinetics. Is It a Buy?
↗
May 18, 2026
Crinetics Pharmaceuticals develops oral therapies for rare endocrine diseases.
Via
The Motley Fool
Topics
ETFs
Regulatory Compliance
FDA Approves Protagonist’s ICOTYDE: The Oral Peptide Revolution Hits the Psoriasis Market
March 23, 2026
In a landmark decision for the dermatology sector, the U.S. Food and Drug Administration (FDA) has officially approved ICOTYDE™ (icotrokinra), a first-of-its-kind oral peptide for the treatment of...
Via
MarketMinute
This New $193 Million Bet Targets a Biotech With $689 Million in Revenue and a Potential Turnaround Story
↗
March 21, 2026
This biotech firm develops therapies for rare, complement-driven diseases, with a focus on autoimmune and inflammatory conditions.
Via
The Motley Fool
Topics
Regulatory Compliance
This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch
↗
March 21, 2026
Cogent Biosciences develops targeted therapies for genetically defined diseases, focusing on precision medicine for rare cancers.
Via
The Motley Fool
Topics
Regulatory Compliance
This Specialized Heart Monitor Maker Just Caught the Eye of a Major Healthcare Fund
↗
March 20, 2026
RTW Investments loads up on iRhythm Holdings with 1.18M Shares Worth $210 million. iRhythm delivers wearable cardiac monitoring and analytics solutions to healthcare providers and at-risk patients.
Via
The Motley Fool
Topics
Regulatory Compliance
Protagonist Stock Up 120%, but One Fund Just Revealed a $170 Million Exit
↗
February 25, 2026
This biotech innovator develops peptide-based therapies for blood and immune disorders, advancing a pipeline of clinical-stage candidates.
Via
The Motley Fool
Topics
Regulatory Compliance
Protagonist Therapeutics Director Sells 20,000 Shares Amid Strong Stock Performance
↗
February 16, 2026
This clinical-stage biotech focused on peptide therapeutics reported significant insider selling amid a year of strong stock performance.
Via
The Motley Fool
Topics
Regulatory Compliance
Protagonist Therapeutics Chief Medical Officer Sells PTGX 9,514 Shares for $784K to Cover Taxes
↗
February 01, 2026
The chief medical officer at one of the top pharmaceutical companies sold nearly 10,000 shares in late January 2026, but the reason was for something very simple.
Via
The Motley Fool
Topics
Regulatory Compliance
"Animal Spirits" Return: Morgan Stanley Signals M&A Renaissance as Healthcare and Industrials Lead Shifting Landscape
January 15, 2026
As 2026 begins, the global mergers and acquisitions (M&A) market is witnessing a profound "renaissance," driven by a confluence of stabilizing interest rates, record levels of corporate cash, and a...
Via
MarketMinute
Topics
Artificial Intelligence
ETFs
Economy
Protagonist (PTGX) Earnings Call Transcript
↗
November 27, 2025
Protagonist (PTGX) Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
What 7 Analyst Ratings Have To Say About Protagonist Therapeutics
↗
October 28, 2025
Via
Benzinga
Moody Aldrich Dumps Entire Stake in Chart Industries Worth $5.8 Million
↗
October 23, 2025
Moody Aldrich Dumps Entire Stake in Chart Industries Worth $5.8 Million
Via
The Motley Fool
Topics
Energy
Moody Aldrich Fully Exits 136K SKWD Shares Worth $7.8 Million
↗
October 23, 2025
Moody Aldrich Fully Exits 136K SKWD Shares Worth $7.8 Million
Via
The Motley Fool
Moody Aldrich Liquidates Entire Stake in PLMR Worth $8.2 Million
↗
October 21, 2025
Moody Aldrich Liquidates Entire Stake in PLMR Worth $8.2 Million
Via
The Motley Fool
Topics
Regulatory Compliance
2 Top Dividend Kings Every Income Investor Should Own
↗
October 20, 2025
These companies pay durable and steadily rising dividends.
Via
The Motley Fool
Topics
Bonds
Johnson & Johnson's M&A Strategy Is the Real Story for Investors
↗
October 18, 2025
Johnson & Johnson’s rumored Protagonist buyout demonstrates its proven M&A strategy: divesting low-growth units to fund high-margin, innovative assets.
Via
MarketBeat
Johnson & Johnson To Separate Orthopedics Business, Boosts Annual Sales Outlook
↗
October 14, 2025
Johnson & Johnson beats Q3 estimates, raises 2025 sales guidance, and announces plans to spin off its $9.2 billion orthopedics business, DePuy Synthes.
Via
Benzinga
Johnson & Johnson Stock Falls Premarket: Investors Eye MedTech Growth, Tariff Impact And Drug Pipeline In Q3 Print
↗
October 14, 2025
Investors may also look for updates on J&J’s reported talks to acquire Protagonist Therapeutics to bolster its immunology and oncology pipeline.
Via
Stocktwits
Topics
Government
World Trade
Johnson & Johnson Q3 Preview: With Stock Near All-Time Highs, Here's What To Watch
↗
October 13, 2025
Johnson & Johnson stock trades near all-time highs with an upcoming Q3 earnings report acting as the next catalyst.
Via
Benzinga
FDA Adds New Warning For Johnson & Johnson's Cancer Cell Therapy
↗
October 13, 2025
FDA updates Johnson & Johnson's Carvykti label to warn of rare immune-related enterocolitis while reaffirming the therapy's overall benefit.
Via
Benzinga
Wall Street Suffers Worst Day Since April as Trump Revives Trade War Fears
↗
October 13, 2025
U.S. markets were rattled on Friday after President Trump reignited trade tensions with China, triggering the sharpest sell-off since April. Tech and AI stocks led the decline, while gold and...
Via
Chartmill
Topics
Artificial Intelligence
Government
World Trade
Why Protagonist Therapeutics Stock Skyrocketed by Almost 30% Today
↗
October 10, 2025
The company could soon be swallowed by a very large peer -- which also happens to be a business partner.
Via
The Motley Fool
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.
↗
October 10, 2025
Wondering how the US markets performed one hour before the close of the markets on Friday? Discover the movers and shakers of today's session in our comprehensive analysis.
Via
Chartmill
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
